Xencor (Caltech) Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement (10/12/2010)

Xencor was founded in 1997 to commercially leverage work performed at Caltech by Dr. Bassil Dahiyat and Dr. Stephen Mayo in the area of proteins and Protein Design Automation.

Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory submission for Phase 1 clinical trials of a novel monoclonal antibody that was optimized using one of Xencor’s XmAb® Fc (constant fragment) technology platforms under a technology license agreement entered in February 2007. The amount of the milestone payment was not disclosed. XmAb® engineered high ADCC Fc domains give antibodies more tumor killing power by improving their capacity to recruit the immune system to target cancer cells, a process called antibody-dependent cell cytotoxicity or ADCC. This program is the third oncology antibody using XmAb® High ADCC technology to enter clinical testing. read more


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: